134 related articles for article (PubMed ID: 23843823)
1. Effects of raloxifene on bone metabolism in hemodialysis patients.
Iwamoto J
Int J Endocrinol Metab; 2012; 10(3):573-5. PubMed ID: 23843823
[No Abstract] [Full Text] [Related]
2. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes.
Saito O; Saito T; Asakura S; Akimoto T; Inoue M; Ando Y; Muto S; Kusano E
Int J Endocrinol Metab; 2012; 10(2):464-9. PubMed ID: 23843805
[TBL] [Abstract][Full Text] [Related]
3. The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.
Saito O; Saito T; Asakura S; Sugase T; Ito C; Ando Y; Muto S; Kusano E
Clin Exp Nephrol; 2011 Feb; 15(1):126-31. PubMed ID: 21069410
[TBL] [Abstract][Full Text] [Related]
4. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
6. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N
Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221
[TBL] [Abstract][Full Text] [Related]
7. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.
Eriguchi R; Umakoshi J; Miura S; Sato Y
Clin Nephrol; 2009 Dec; 72(6):423-9. PubMed ID: 19954718
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of renal osteodystrophy with cortical quantitative ultrasound at various bone sites.
da Costa JA; de Castro JA; Foss MC
Ren Fail; 2004 May; 26(3):237-41. PubMed ID: 15354971
[TBL] [Abstract][Full Text] [Related]
9. Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy.
Paggiosi MA; Clowes JA; Finigan J; Naylor KE; Peel NF; Eastell R
J Clin Densitom; 2010; 13(4):441-50. PubMed ID: 20850365
[TBL] [Abstract][Full Text] [Related]
10. Quantitative ultrasound of the calcaneus in hemodialysis patients.
Kuo CW; Ho SY; Chang TH; Chu TC
Ultrasound Med Biol; 2010 Apr; 36(4):589-94. PubMed ID: 20211518
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes.
Mori H; Okada Y; Kishikawa H; Inokuchi N; Sugimoto H; Tanaka Y
J Bone Miner Metab; 2013 Jan; 31(1):89-95. PubMed ID: 22868657
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
[TBL] [Abstract][Full Text] [Related]
13. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
[TBL] [Abstract][Full Text] [Related]
14. Effects of a Combination Therapy of Sclerostin Antibody III and Raloxifene on Bone Formation Markers in Ovariectomized Rats.
Gad Allam HI
J Coll Physicians Surg Pak; 2016 Jan; 26(1):46-50. PubMed ID: 26787031
[TBL] [Abstract][Full Text] [Related]
15. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
[TBL] [Abstract][Full Text] [Related]
17. Multiple forms of alkaline phosphatase in plasma of hemodialysis patients.
Tibi L; Chhabra SC; Sweeting VM; Winney RJ; Smith AF
Clin Chem; 1991 Jun; 37(6):815-20. PubMed ID: 1675597
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene increases serum leptin levels in postmenopausal women: a prospective study.
Cakmak A; Posaci C; Dogan E; Caliskan S; Guclu S; Altunyurt S
Am J Obstet Gynecol; 2005 Aug; 193(2):347-51. PubMed ID: 16098853
[TBL] [Abstract][Full Text] [Related]
19. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
